What is EnGen Bio?
EnGen Bio is an independent pharmaceutical company dedicated to pioneering a vaccine designed to provide lifelong immunity against Type A influenza. Their innovative approach targets a unique epitope on the M1 matrix protein of the flu virus, with the goal of stimulating durable and broadly neutralizing antibody responses. This focus addresses the critical global challenge posed by influenza pandemics. The company's intellectual property portfolio includes nine patents, reinforcing its discoveries and development efforts.
How much funding has EnGen Bio raised?
EnGen Bio has raised a total of $41K across 1 funding round:
Debt
$41K
Debt (2021): $41K with participation from PPP
What's next for EnGen Bio?
With significant backing and a clear technological advantage, EnGen Bio is poised to advance its vaccine candidate through critical development milestones. The substantial expansion capital will likely fuel clinical trials, manufacturing scale-up, and regulatory submissions. The company's focus on a novel mechanism for long-lasting immunity positions it to potentially disrupt the influenza vaccine market, offering a compelling alternative to existing annual vaccinations and addressing the persistent threat of pandemic strains.
See full EnGen Bio company page
